Trial · NCT03142568
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety as Determined by Adverse Event Experienced by Participants | Sildenafil Cohort 1 | 71 | Events | ||
| Safety as Determined by Adverse Event Experienced by Participants | Sildenafil Cohort 2 | 83 | Events | ||
| Safety as Determined by Adverse Event Experienced by Participants | Sildenafil Cohort 3 | 53 | Events | ||
| Safety as Determined by Adverse Event Experienced by Participants | Placebo Total | 60 | Events | ||
| Volume of Distribution | Sildenafil Cohort 1 | 3.01 | Full Range 1.78 to 17.25 | L/kg | |
| Volume of Distribution | Sildenafil Cohort 2 | 3.67 | Full Range 1.62 to 24.52 | L/kg | |
| Volume of Distribution | Sildenafil Cohort 3 | 3.07 | Full Range 1.71 to 8.78 | L/kg | |
| Clearance | Sildenafil Cohort 1 | 1.23 | Full Range 0.46 to 4.24 | L/h/kg | |
| Clearance | Sildenafil Cohort 2 | 1.54 | Full Range 0.46 to 4.20 | L/h/kg | |
| Clearance | Sildenafil Cohort 3 | 1.30 | Full Range 0.41 to 6.73 | L/h/kg | |
| Half-Life | Sildenafil Cohort 1 | 7.89 | Full Range 6.14 to 11.19 | hours | |
| Half-Life | Sildenafil Cohort 2 | 7.87 | Full Range 5.02 to 11.45 | hours | |
| Half-Life | Sildenafil Cohort 3 | 7.46 | Full Range 6.62 to 12.14 | hours | |
| Area Under the Curve (AUC) | Sildenafil Cohort 1 | 174.0 | Full Range 46.94 to 452.13 | ng*h/mL | |
| Area Under the Curve (AUC) | Sildenafil Cohort 2 | 610.50 | Full Range 245.86 to 2342.48 | ng*h/mL | |
| Area Under the Curve (AUC) | Sildenafil Cohort 3 | 1196.78 | Full Range 254.74 to 1983.73 | ng*h/mL | |
| Peak Plasma Concentration | Sildenafil Cohort 1 | 11.51 | Full Range 5.17 to 53.62 | ng/mL | |
| Peak Plasma Concentration | Sildenafil Cohort 2 | 39.72 | Full Range 23.50 to 301.82 | ng/mL | |
| Peak Plasma Concentration | Sildenafil Cohort 3 | 84.36 | Full Range 20.36 to 134.89 | ng/mL | |
| Change in Moderate-severe BPD or Death | Sildenafil Cohort 1 | Risk of moderate BPD, severe BPD or Death (%) at study week 0 | 66.3 | Standard Deviation 20.1 | Percent probability of risk BPD or death |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03142568/results